NASDAQ:RAPT RAPT Therapeutics (RAPT) Stock Price, News & Analysis → The AI Bottleneck No One is Talking About (From The Bull Report) (Ad) Free RAPT Stock Alerts $8.33 -0.14 (-1.65%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$8.15▼$8.6750-Day Range$6.87▼$26.4552-Week Range$6.86▼$27.35Volume795,749 shsAverage Volume1.33 million shsMarket Capitalization$289.88 millionP/E RatioN/ADividend YieldN/APrice Target$25.89 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get RAPT Therapeutics alerts: Email Address RAPT Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside210.8% Upside$25.89 Price TargetShort InterestHealthy7.16% of Shares Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment0.60Based on 2 Articles This WeekInsider TradingSelling Shares$74,656 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.24) to ($2.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.68 out of 5 starsMedical Sector64th out of 947 stocksPharmaceutical Preparations Industry24th out of 435 stocks 4.3 Analyst's Opinion Consensus RatingRAPT Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.89, RAPT Therapeutics has a forecasted upside of 210.8% from its current price of $8.33.Amount of Analyst CoverageRAPT Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.16% of the outstanding shares of RAPT Therapeutics have been sold short.Short Interest Ratio / Days to CoverRAPT Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RAPT Therapeutics has recently decreased by 29.06%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRAPT Therapeutics does not currently pay a dividend.Dividend GrowthRAPT Therapeutics does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRAPT Therapeutics has received a 42.76% net impact score from Upright. Rapt Therapeutics seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for RAPT Therapeutics is -0.87. Previous Next 2.6 News and Social Media Coverage News SentimentRAPT Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for RAPT Therapeutics this week, compared to 2 articles on an average week.Search Interest19 people have searched for RAPT on MarketBeat in the last 30 days. This is an increase of 1,800% compared to the previous 30 days.MarketBeat Follows7 people have added RAPT Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RAPT Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,656.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of RAPT Therapeutics is held by insiders.Percentage Held by Institutions99.09% of the stock of RAPT Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for RAPT Therapeutics are expected to grow in the coming year, from ($3.24) to ($2.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RAPT Therapeutics is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RAPT Therapeutics is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRAPT Therapeutics has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About RAPT Therapeutics Stock (NASDAQ:RAPT)RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Read More RAPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RAPT Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comRAPT Apr 2024 10.000 putMarch 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTMarch 19, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 11, 2024 | markets.businessinsider.comHold Rating on RAPT Therapeutics Amid Clinical Trial Uncertainties and Financial ConcernsMarch 10, 2024 | americanbankingnews.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMarch 8, 2024 | finance.yahoo.comRAPT Oct 2024 5.000 callMarch 7, 2024 | investorplace.comRAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023March 7, 2024 | globenewswire.comRAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 19, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.March 5, 2024 | globenewswire.comRAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual MeetingMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTFebruary 26, 2024 | businesswire.comRAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsFebruary 23, 2024 | finance.yahoo.comRAPT May 2024 17.500 putFebruary 22, 2024 | msn.comUBS Downgrades RAPT Therapeutics (RAPT)February 21, 2024 | msn.comHC Wainwright & Co. Downgrades RAPT Therapeutics (RAPT)February 21, 2024 | msn.comLeerink Partners Downgrades RAPT Therapeutics (RAPT)February 21, 2024 | realmoney.thestreet.comRapt Therapeutics just downgraded at Leerink, here's whyFebruary 21, 2024 | msn.comJ.P. Morgan cuts RAPT to neutral, recommends against buying dipFebruary 21, 2024 | msn.comH.C. Wainwright cuts RAPT to neutral, cites delays due to clinical holdFebruary 21, 2024 | markets.businessinsider.comWhat's Going On With RAPT Therapeutics Stock On Wednesday?February 21, 2024 | finance.yahoo.comInsider Buyers Lose Additional US$63k As RAPT Therapeutics Dips To US$236mFebruary 21, 2024 | realmoney.thestreet.comRapt Therapeutics just downgraded at JPMorgan, here's whyFebruary 21, 2024 | msn.comRAPT Therapeutics (NASDAQ:RAPT) Crashes 60% after FDA Places Clinical HoldFebruary 20, 2024 | realmoney.thestreet.comRapt Therapeutics just downgraded at Cantor Fitzgerald, here's whyFebruary 20, 2024 | bizjournals.comPeninsula biotech halts 2 clinical trials, stock loses 70% of valueFebruary 20, 2024 | finance.yahoo.comRapt Therapeutics Crashes 74% After Unexpected Liver Failure Sidelines Two TestsFebruary 20, 2024 | markets.businessinsider.comFDA Puts Hold On RAPT's Phase 2 Trials For Zelnecirnon In Atopic Dermatitis, Asthma; Stock Tanks 65%See More Headlines Receive RAPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2023Today3/19/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RAPT CUSIPN/A CIK1673772 Webwww.rapt.com Phone(650) 489-9000FaxN/AEmployees129Year Founded2015Price Target and Rating Average Stock Price Target$25.89 High Stock Price Target$41.00 Low Stock Price Target$10.00 Potential Upside/Downside+210.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-116,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-63.14% Return on Assets-55.48% Debt Debt-to-Equity RatioN/A Current Ratio7.41 Quick Ratio7.41 Sales & Book Value Annual Sales$1.53 million Price / Sales189.47 Cash FlowN/A Price / Cash FlowN/A Book Value$4.27 per share Price / Book1.95Miscellaneous Outstanding Shares34,800,000Free Float32,884,000Market Cap$289.88 million OptionableOptionable Beta0.47 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Brian Russell Wong M.D. (Age 52)Ph.D., CEO, President & Director Comp: $797.5kMr. Rodney K. B. Young (Age 61)CFO, Principal Accounting Officer & Secretary Comp: $585kDr. William Ho (Age 58)Chief Medical Officer Comp: $590kSteve Young Ph.D.Vice President of TechnologyDr. Dirk G. Brockstedt Ph.D. (Age 55)Chief Scientific Officer Comp: $490.25kMr. Michael ListgartenGeneral CounselMs. Gwen R. Carscadden (Age 63)Chief Human Resources Officer Dr. Paul Kassner (Age 57)Senior Vice President of Quantitative & Computational Biology Dr. David Wustrow (Age 65)Senior Vice President of Drug Discovery & Preclinical Development Ms. Jennifer NicholsonSenior Vice President of Regulatory Affairs & Quality AssuranceMore ExecutivesKey CompetitorsFoghorn TherapeuticsNASDAQ:FHTXVerastemNASDAQ:VSTMWerewolf TherapeuticsNASDAQ:HOWLAkebia TherapeuticsNASDAQ:AKBAIncannex HealthcareNASDAQ:IXHLView All CompetitorsInsiders & InstitutionsKingdon Capital Management L.L.C.Bought 160,000 shares on 3/18/2024Ownership: 2.775%Vanguard Group Inc.Bought 32,916 shares on 3/11/2024Ownership: 5.909%Perceptive Advisors LLCBought 219,292 shares on 2/26/2024Ownership: 6.221%Price T Rowe Associates Inc. MDSold 126,289 shares on 2/16/2024Ownership: 9.923%GSA Capital Partners LLPSold 10,281 shares on 2/16/2024Ownership: 0.059%View All Insider TransactionsView All Institutional Transactions RAPT Stock Analysis - Frequently Asked Questions Should I buy or sell RAPT Therapeutics stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last twelve months. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RAPT shares. View RAPT analyst ratings or view top-rated stocks. What is RAPT Therapeutics' stock price target for 2024? 12 Wall Street research analysts have issued twelve-month price objectives for RAPT Therapeutics' shares. Their RAPT share price targets range from $10.00 to $41.00. On average, they expect the company's share price to reach $25.89 in the next year. This suggests a possible upside of 210.8% from the stock's current price. View analysts price targets for RAPT or view top-rated stocks among Wall Street analysts. How have RAPT shares performed in 2024? RAPT Therapeutics' stock was trading at $24.85 at the beginning of the year. Since then, RAPT stock has decreased by 66.5% and is now trading at $8.33. View the best growth stocks for 2024 here. Are investors shorting RAPT Therapeutics? RAPT Therapeutics saw a decrease in short interest in the month of February. As of February 29th, there was short interest totaling 2,490,000 shares, a decrease of 29.1% from the February 14th total of 3,510,000 shares. Based on an average daily trading volume, of 1,130,000 shares, the days-to-cover ratio is presently 2.2 days. View RAPT Therapeutics' Short Interest. When is RAPT Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our RAPT earnings forecast. How were RAPT Therapeutics' earnings last quarter? RAPT Therapeutics, Inc. (NASDAQ:RAPT) announced its earnings results on Friday, August, 11th. The company reported ($0.66) earnings per share for the quarter, topping analysts' consensus estimates of ($0.78) by $0.12. What ETFs hold RAPT Therapeutics' stock? ETFs with the largest weight of RAPT Therapeutics (NASDAQ:RAPT) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What is Brian Wong's approval rating as RAPT Therapeutics' CEO? 8 employees have rated RAPT Therapeutics Chief Executive Officer Brian Wong on Glassdoor.com. Brian Wong has an approval rating of 100% among the company's employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of RAPT Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include NVIDIA (NVDA), Boeing (BA), Slack Technologies (WORK), Overstock.com (OSTK), Salesforce (CRM), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Livongo Health (LVGO), Mastercard (MA) and QUALCOMM (QCOM). When did RAPT Therapeutics IPO? (RAPT) raised $39 million in an initial public offering on Thursday, October 31st 2019. The company issued 3,000,000 shares at $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank acted as the underwriters for the IPO. Who are RAPT Therapeutics' major shareholders? RAPT Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (9.92%), Price T Rowe Associates Inc. MD (9.92%), Perceptive Advisors LLC (6.22%), Vanguard Group Inc. (5.98%), Vanguard Group Inc. (5.91%) and Great Point Partners LLC (3.20%). Insiders that own company stock include Dirk G Brockstedt, Dirk G Brockstedt, Gino Dellomo, Group Ii Lp Column, Phuong Y Phillips, Rodney Kb Young, Wendye Robbins and William Ho. View institutional ownership trends. How do I buy shares of RAPT Therapeutics? Shares of RAPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RAPT) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RAPT Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.